Treatment of head and neck dermatitis with ciclopiroxolamine cream - Results of a double-blind, placebo-controlled study

Skin Pharmacology and Physiology

Volumn 19, Issue 3, 2006, Pages 153-158

  Mayser, Peter ^a,c   Kupfer, Jörg ^b   Nemetz, Diana ^a   Schäfer, Ute ^a   Nilles, Martin ^a   Hort, Wiebke ^a   Gieler, Uwe ^b  

^a Center for Dermatology and Andrology   (Germany)

^b Center for Internal Medicine   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Antimycotic therapy; Atopic dermatitis; Ciclopiroxolamine; Head and neck dermatitis; Malassezia

Indexed keywords

ANTIFUNGAL AGENT; CICLOPIROXOLAMINE; DAKTACORT; FLUCLOXACILLIN; HYDROCORTISONE; ITRACONAZOLE; KETOCONAZOLE; PLACEBO; PREDNICARBATE; SHAMPOO;

ARTICLE; ATOPIC DERMATITIS; ATOPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HEAD AND NECK DISEASE; HUMAN; MALASSEZIA; MALASSEZIA FURFUR; MALASSEZIA SYMPODIALIS; MALE; PRICK TEST; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; ENTEROTOXINS; FEMALE; HEAD; HUMANS; IMMUNOGLOBULIN E; MALASSEZIA; MALE; MIDDLE AGED; NECK; PYRIDONES;

EID: 33745234814     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092596     Document Type: Article

References (26)

1. Ring J, Abeck D, Neuber K: Atopic eczema: role of microorganisms on the skin surface. Allergy 1992;47:265-269.
2. Roll A, Cozzio A, Fischer B, Schmid-Grendelmeier P: Microbial colonization and atopic dermatitis. Curr Opin Allergy Clin Immunol 2004;4:373-378.
3. Scheynius A, Johansson C, Buentke E, Zargari A, Tengvall Linder M: Atopic eczema/dermatitis syndrome and Malassezia. Int Arch Allergy Immunol 2002;127:161-169.
4. Aspres N, Anderson C: Malassezia yeasts in the pathogenesis of atopic dermatitis. Australas J Dermatol 2004;45:199-207.
5. Gueho E, Midgley G, Guillot J: The genus Malassezia with description of four new species. Antonie van Leewenhoek 1996;69:337-355.
6. Sugita T, Takashima M, Shinoda T, Suto H, et al: New yeast species, Malassezia dermatis, isolated from patients with atopic dermatitis. J Clin Microbiol 2002;40:1363-1367.
7. Sugita T, Kodama M, Tsuboi R, Nishikawa A: Description of a new yeasts species, Malassezia japonica, and its detection in patients with atopic dermatitis and healthy subjects. J Clin Microbiol 2003;41:4695-4699.
8. Ashbee HR, Evans EGV: Immunology of diseases associated with Malassezia species. Clin Microbiol Rev 2002;15:21-57.
9. Nikkels AF, Piérard GE: Framing the future of antifungals in atopic dermatitis. Dermatology 2003;206:398-400.
10. Andersson A, Rasool O, Schmidt M, Kodzius R, Flückiger S, Zargari A, Crameri R, Scheynius A: Cloning, expression and characterization of two new IgE-binding proteins from the yeast Malassezia sympodialis with sequence similarities to heat shock proteins and manganese superoxide dismutase. Eur J Biochem 2004;27:1885-1894.
11. Clemmensen OJ, Hjorth N: Treatment of dermatitis of the head and neck with ketoconazole in patients with type I sensitivity to Pityrosporum orbiculare. Semin Dermatol 1983;2:26-29.
12. Bäck O, Scheynius A, Johansson SGO: Ketoconazole in atopic dermatitis: therapeutic response is correlated with decrease in serum IgE. Arch Dermatol Res 1995;287:448-451.
13. Bäck O, Bartosik J: Systemic ketoconazole for yeast allergic patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2001;15:34-38.
14. Lintu P, Savolainen J, Kortekangas-Savolainen O, Kalimo K: Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeast. Allergy 2001;56:512-517.
15. Svejgaard E, Larsen PO, Deleuran M, Ternowitz T, Roed-Petersen J, Nilsson J: Treatment of head and neck dermatitis comparing itraconazole 200 and 400 mg daily for 1 week with placebo. J Eur Acad Dermatol Venereol 2004;18:445-449.
16. Broberg A, Faergemann J: Topical antimycotic treatment of atopic dermatitis in the head/neck area. A double-blind randomized study. Acta Derm Venereol 1995;75:46-49.
17. Gupta AK: Ciclopirox: an overview. Int J Dermatol 2001;40:305-310.
18. Kokjohn K, Bradley M, Griffiths B, Ghannoum M: Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria. Int J Dermatol 2003;42(suppl 1):11-17.
19. Lassus A, Nolting KS, Savopoulos C: Comparison of ciclopiroxolamine 1% cream with ciclopirox 1%-hydrocortisone acetate 1% cream in the treatment of inflamed superficial mycoses. Clin Ther 1988;10:594-599.
20. Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980;92(suppl):44-47.
21. Wahn U, Bos JD, Goodfield M, Caputo R, et al: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:e2.
22. Tofte S, et al: J Eur Acad Dermatol Venereol 1998;11(suppl 2):197.
23. Johansson C, Sandström MH, Bartosik J, Särnhult T, Christiansen J, Zargari A, Bäck O, Wahlgren CF, Faergemann J, Scheynius A, Tengvall-Linder M: Atopy patch test reactions to Malassezia allergens differentiate subgroups of atopic dermatitis patients 2003;148:479-488.
24. Zargari A, Midgley G, Bäck O, Johansson SGO, Scheynius A: IgE-reactivity to seven Malassezia species. Allergy 2003;58:306-311.
25. Zargari A, Eshaghi H, Bäck O, Johansson SGO, Scheynius A: Serum IgE reactivity to Malassezia furfur extract and recombinant M. furfur allergens in patients with atopic dermatitis. Acta Derm Venereol 2001;81:418-422.
26. Sugita T, Tajima M, Amaya M, Tsuboi R, Nishikawa A: Genotype analysis of Malassezia restricta as the major cutaneous flora in patients with atopic dermatitis and healthy subjects. Microbiol Immunol 2004;48:755-759.